Telix Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

De CEO Telix Pharmaceuticals is Chris Behrenbruch, benoemd in Jul2023, heeft een ambtstermijn van 1.33 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.02M, bestaande uit 49% salaris en 51% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 6.94% van de aandelen van het bedrijf, ter waarde A$ 515.67M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 7.2 jaar.

Belangrijke informatie

Chris Behrenbruch

Algemeen directeur

AU$1.0m

Totale compensatie

Percentage CEO-salaris	49.0%
Dienstverband CEO	1.3yrs
Eigendom CEO	6.9%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	7.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Behrenbruch's beloning veranderd ten opzichte van Telix Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	AU$49m
Mar 31 2024	n/a	n/a	AU$32m
Dec 31 2023	AU$1m	AU$499k	AU$5m
Sep 30 2023	n/a	n/a	-AU$21m
Jun 30 2023	n/a	n/a	-AU$48m
Mar 31 2023	n/a	n/a	-AU$77m
Dec 31 2022	AU$865k	AU$422k	-AU$104m
Sep 30 2022	n/a	n/a	-AU$111m
Jun 30 2022	n/a	n/a	-AU$119m
Mar 31 2022	n/a	n/a	-AU$100m
Dec 31 2021	AU$620k	AU$374k	-AU$81m
Sep 30 2021	n/a	n/a	-AU$70m
Jun 30 2021	n/a	n/a	-AU$59m
Mar 31 2021	n/a	n/a	-AU$52m
Dec 31 2020	AU$421k	AU$295k	-AU$45m
Sep 30 2020	n/a	n/a	-AU$40m
Jun 30 2020	n/a	n/a	-AU$36m
Mar 31 2020	n/a	n/a	-AU$32m
Dec 31 2019	AU$460k	AU$317k	-AU$28m
Sep 30 2019	n/a	n/a	-AU$23m
Jun 30 2019	n/a	n/a	-AU$19m
Mar 31 2019	n/a	n/a	-AU$16m
Dec 31 2018	AU$380k	AU$280k	-AU$14m
Sep 30 2018	n/a	n/a	-AU$12m
Jun 30 2018	n/a	n/a	-AU$10m
Mar 31 2018	n/a	n/a	-AU$8m
Dec 31 2017	AU$303k	AU$211k	-AU$6m

Compensatie versus markt: De totale vergoeding ($USD 663.41K ) Chris } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 2.70M ).

Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Chris Behrenbruch (48 yo)

1.3yrs

Tenure

AU$1,018,461

Compensatie

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christian Behrenbruch	Co-Founder	1.3yrs	AU$1.02m	6.94% A$ 515.7m
Darren Smith	Group Chief Financial Officer	2.3yrs	AU$713.90k	0.0019% A$ 144.1k
Andreas Kluge	Chief Medical Advisor	no data	AU$43.00k	6.78% A$ 503.4m
David Cade	Group Chief Medical Officer	less than a year	geen gegevens	0.11% A$ 8.3m
Richard Valeix	Chief Executive Officer of Telix Therapeutics	3.5yrs	AU$902.90k	0.060% A$ 4.4m
Darren Patti	Group Chief Operating Officer	less than a year	geen gegevens	0% A$ 0
Michael Wheatcroft	Chief Scientist	3.5yrs	AU$167.76k	geen gegevens
Craig Ulrick	Chief Information Officer	1.8yrs	geen gegevens	geen gegevens
Kyahn Williamson	Senior Vice President of Corporate Communications & Investor Relations	3.3yrs	geen gegevens	geen gegevens
Lena Moran-Adams	Group General Counsel	2.2yrs	geen gegevens	geen gegevens
Thomas Fromm	Vice President of Sales	no data	geen gegevens	geen gegevens
Meredith Crowe	Senior Vice President of Global People & Culture	2.2yrs	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TLX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christian Behrenbruch	Co-Founder	7.8yrs	AU$1.02m	6.94% A$ 515.7m
Harry McCann	Independent Non-Executive Chairman	7.2yrs	AU$188.28k	0.34% A$ 25.5m
Chaitanya Divgi	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Rodney Hicks	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Neil Bander	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mark Nelson	Independent Non-Executive Director	7.2yrs	AU$103.30k	1.08% A$ 80.6m
Jann Skinner	Independent Non-Executive Director	6.4yrs	AU$111.56k	0.18% A$ 13.2m
Jean-François Chatal	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jason Lewis	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Klaus Kopka	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Samuel Samnick	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Richard Baum	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.2yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TLX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.2 jaar).

Telix Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Co-Founder exercised options to buy AU$1.7m worth of stock.

Telix Pharmaceuticals Limited Announces Executive Changes

Insider recently bought AU$343k worth of stock

Insider recently bought AU$73k worth of stock

Recent updates

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Consensus EPS estimates fall by 23%

Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent

Second quarter 2024 earnings: EPS misses analyst expectations

Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

Price target increased by 12% to AU$24.04

Price target increased by 10% to AU$20.87

Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024

Price target increased by 14% to AU$21.49

Consensus EPS estimates increase by 10%

Price target increased by 11% to AU$18.89

Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million.

First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023)

Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent

Consensus EPS estimates increase by 10%

Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.

Consensus EPS estimates increase by 30%

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

Now 20% overvalued after recent price rise

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent

Consensus EPS estimates fall by 19%

Price target increased by 7.5% to AU$14.47

Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million.

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.

Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022)

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Co-Founder exercised options to buy AU$1.7m worth of stock.

Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Price target increased by 8.0% to AU$13.37

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million.

Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591

Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies

Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023

New minor risk - Shareholder dilution

Forecast to breakeven in 2023

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.23 loss in 1H 2022)

Forecast to breakeven in 2023

Forecast breakeven date moved forward to 2023

Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023

Forecast to breakeven in 2023

Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023

Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Price target increased by 7.5% to AU$11.82

Price target increased by 8.8% to AU$10.54

Price target increased by 8.8% to AU$10.54

Insider recently bought AU$343k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial

Consensus EPS estimates fall by 14%, revenue upgraded

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023

Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Insider recently bought AU$73k worth of stock